Real-world stool metagenomics analysis in integrative oncology
Consecutive patients undergoing metagenomic stool profiling in routine care between January 2025 and March 2026 were included. Cohorts were defined a priori by treatment status at sampling. Cohort 1 (active treatment): systemic anticancer therapy other than endocrine therapy, including chemotherapy, targeted agents, antibody-drug conjugates, tyrosine kinase inhibitors, demethylating agents and immune checkpoint inhibitors (ICIs). Cohort 2 (endocrine therapy): endocrine treatment only. Cohort 3 (off treatment): no systemic anticancer therapy at sampling.
Consecutive patients undergoing metagenomic stool profiling in routine care between January 2025 and March 2026 were included. Cohorts were defined a priori by treatment status at sampling. Cohort 1 (active treatment): systemic anticancer therapy other than endocrine therapy, including chemotherapy, targeted agents, antibody-drug conjugates, tyrosine kinase inhibitors, demethylating agents and immune checkpoint inhibitors (ICIs). Cohort 2 (endocrine therapy): endocrine treatment only. Cohort 3 (off treatment): no systemic anticancer therapy at sampling.